March 1, 2008

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

.   .   

Related Articles:

  • Visitor

    I found this article very interesting and rather worrisome. It has been my practice to treat patients with malignancy, renal insufficiency with epo for anemia. I think that I would have a higher threshold now for using an erythropoietin agent. I would be interested in the thoughts of more experienced nephrologists.

  • chchanmysia

    I think we wish to see a result from more bigger data base for reference. Clinically, the higher EPO dosage provide higher Hemoglobin level & better lactivity & life quality, if the other factor already corrected. So….